Ahen Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 38.13%
- Profit Growth -76.33%
- Ebitda -24.14%
- Net Worth 2.42%
- Total Assets 157.61%
About Ahen Pharmaceuticals
Ahen Pharmaceuticals Private Limited (APPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 08 May 2019 (Five years and nine months 3 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nongthombam Meitei, Aribam Sharma, and Nongthombam Meitei serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24302GJ2019PTC108047
-
Company No.
108047
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 May 2019
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Ahen Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nongthombam Meitei
|
Director | 08-May-2019 | Current |
|
Aribam Sharma
|
Director | 08-May-2019 | Current |
|
Nongthombam Meitei
|
Director | 08-May-2019 | Current |
Financial Performance of Ahen Pharmaceuticals.
Ahen Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 38.13% increase. The company also saw a substantial fall in profitability, with a 76.33% decrease in profit. The company's net worth moved up by a moderate rise of 2.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ahen Pharmaceuticals?
In 2023, Ahen Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ahen Pharmaceuticals?
Ahen Pharmaceuticals has a workforce of 13 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ahen Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ahen Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
